Tumor vessel types in RCC, HCC, thyroid cancer are respond, but stromal vessel types in CRC, breast cancer, prostate cancer are refractory to a single anti-VEGF therapy [40]. This evidence concerns the gene VEGFA and Familial prostate cancer.